오토인젝터 시장 예측(-2031년) : 유형별, 사용법별, 작동 기구별, 투여 경로별, 치료 영역별, 약제 유형별, 용량별, 최종사용자별, 지역별

The global autoinjectors market is projected to reach USD 300.46 billion by 2031 from USD 127.30 billion in 2026, at a CAGR of 18.7% during the forecast period.

The demand for autoinjectors is experiencing steady growth, fueled by the increasing prevalence of chronic and autoimmune diseases and the growing global population. The rising adoption of autoinjectors for long-term treatments, along with the shift toward home-based care, is boosting product use. Patients are seeking high-quality, safe, and easy-to-use autoinjectors to ensure accurate drug delivery and safety. Technological advances such as needle-free autoinjectors, smart connected devices, and built-in sensors are further increasing market adoption. Additionally, expanding healthcare infrastructure in emerging economies and supportive government initiatives promoting modern healthcare are expected to maintain strong market growth in the coming years.

"By drug type, the biologics segment is projected to capture a significant market share."

Based on drug type, biologics are the dominant segment in the autoinjectors market, driven by their increased use in treating chronic and autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, and diabetes. Furthermore, growing investments in biotechnology and biosimilar development, along with increasing regulatory approvals for biologics, are further boosting demand. Many biologics require parenteral administration, making them compatible with autoinjectors. The expanding pipeline of monoclonal antibodies and other biologic injectables is also accelerating demand.

"By route of administration, the subcutaneous route of administration segment is expected to register the largest share in 2025."

By route of administration, the subcutaneous route holds the largest share in the autoinjectors market because it allows drugs to be delivered with less pain than the intramuscular route, due to reduced penetration depth. The subcutaneous route is favored for biologic therapies because it provides consistent drug absorption and better patient compliance. The increasing prevalence of chronic and acute diseases, along with more hospital admissions, continues to boost demand for long-term treatments, which further increases the demand for autoinjectors.

In 2025, North America accounted for the largest share of the autoinjectors market by region.

The autoinjectors market is divided into North America, Europe, Latin America, Asia Pacific, and the Middle East & Africa. North America dominates the global autoinjectors market; this leadership is due to the high prevalence of chronic diseases, an established healthcare infrastructure, and rapid adoption of advanced medical technologies. Moreover, the strong presence of key market players, increased healthcare spending, and rising demand for advanced infusion systems in hospitals and home healthcare settings all support the region's dominant market position.

A breakdown of the primary participants referred to for this report is provided below:

• By Company Type: Tier 1-40%, Tier 2-35%, and Tier 3- 25%
• By Designation: Directors-23%, Managers-30%, and Others-47%
• By Region: North America-25%, Europe-35%, Asia Pacific-20%, Latin America- 13%, and the Middle East & Africa- 7%

The prominent players in the autoinjector devices market include Becton, Dickinson and Company (US), SHL Medical (Switzerland), and Ypsomed (Switzerland). However, prominent players in the autoinjector finished formulation market include Novo Nordisk (Denmark), Eli Lilly and Company (US), and AbbVie (US).

Research Coverage

This report examines the autoinjectors market based on type, usage, actuation mechanism, route of administration, therapy area, drug type, volume, end user, and region. It also discusses the factors influencing market growth, analyzes various opportunities and challenges, and provides details about the competitive landscape for market leaders. Additionally, the report analyzes micro markets in terms of their individual growth trends and forecasts the revenue of market segments across five main regions (and the respective countries within these regions).

Reasons to Buy the Report

The report will help both established and smaller firms understand the market better, which, in turn, will assist them in gaining a larger market share. Companies purchasing the report can use one or a combination of the strategies below to strengthen their market position.

This report provides insights into the following pointers:

Analysis of key drivers (rising prevalence of chronic diseases, Increasing regulatory approvals, high demand for biosimilars and biologics, growing adoption of self-administered medicines, government support and favorable reimbursement policies), restraints (focus on needle-free drug delivery systems and prevalence of needle phobia), opportunities (impending patent expiry of biological molecules, launch of technologically advanced autoinjectors, untapped opportunities in emerging markets), and challenges (development of autoinjectors for multiple drug viscosities, risk of device malfunctions and recalls) influencing the growth of autoinjectors market

• Market Penetration: Comprehensive information on the product portfolios offered by the top players in the autoinjectors market
• Product Development/Innovation: Detailed insights into the upcoming trends, R&D activities, and product developments in the autoinjectors market
• Market Development: Comprehensive information on lucrative emerging regions
• Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the autoinjectors market
• Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 SEGMENTS CONSIDERED
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

• 2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS
• 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
• 2.3 DISRUPTIVE TRENDS IN AUTOINJECTORS MARKET
• 2.4 HIGH-GROWTH SEGMENTS
• 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

• 3.1 AUTOINJECTORS MARKET OVERVIEW
• 3.2 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY COUNTRY AND USAGE
• 3.3 ASIA PACIFIC: FINISHED FORMULATION AUTOINJECTORS MARKET, BY COUNTRY AND ACTUATION MECHANISM
• 3.4 GEOGRAPHIC SNAPSHOT OF AUTOINJECTOR DEVICES MARKET
• 3.5 GEOGRAPHIC SNAPSHOT OF FINISHED FORMULATION AUTOINJECTORS MARKET

4 MARKET OVERVIEW

• 4.1 INTRODUCTION
• 4.2 MARKET DYNAMICS
  • 4.2.1 DRIVERS
    • 4.2.1.1 Rising prevalence of chronic and autoimmune diseases
    • 4.2.1.2 Increasing regulatory approvals for autoinjectors
    • 4.2.1.3 High demand for biosimilars and biologics
    • 4.2.1.4 Growing adoption of self-administered medicines
    • 4.2.1.5 Government support and favorable reimbursement policies
  • 4.2.2 RESTRAINTS
    • 4.2.2.1 Focus on needle-free drug delivery systems and prevalence of needle phobia
  • 4.2.3 OPPORTUNITIES
    • 4.2.3.1 Impending patent expiry of biological molecules
    • 4.2.3.2 Launch of technologically advanced autoinjectors
    • 4.2.3.3 Untapped opportunities in emerging markets
  • 4.2.4 CHALLENGES
    • 4.2.4.1 Development of autoinjectors for multiple drug viscosities
    • 4.2.4.2 Risk of device malfunctions and recalls
• 4.3 UNMET NEEDS AND WHITE SPACES
  • 4.3.1 UNMET NEEDS IN AUTOINJECTORS MARKET
  • 4.3.2 WHITE SPACE OPPORTUNITIES
• 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
  • 4.4.1 INTERCONNECTED MARKETS
  • 4.4.2 CROSS-SECTOR OPPORTUNITIES
• 4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS

5 INDUSTRY TRENDS

• 5.1 PORTER'S FIVE FORCES ANALYSIS
  • 5.1.1 THREAT OF NEW ENTRANTS
  • 5.1.2 THREAT OF SUBSTITUTES
  • 5.1.3 BARGAINING POWER OF SUPPLIERS
  • 5.1.4 BARGAINING POWER OF BUYERS
  • 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.2 MACROECONOMIC OUTLOOK
  • 5.2.1 INTRODUCTION
  • 5.2.2 GDP TRENDS AND FORECAST
  • 5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY
  • 5.2.4 TRENDS IN GLOBAL MEDICAL DEVICE INDUSTRY
• 5.3 SUPPLY CHAIN ANALYSIS
• 5.4 VALUE CHAIN ANALYSIS
• 5.5 MARKET ECOSYSTEM
  • 5.5.1 AUTOINJECTORS MARKET PROVIDERS
  • 5.5.2 END USERS
  • 5.5.3 REGULATORY BODIES
• 5.6 PRICING ANALYSIS
  • 5.6.1 AVERAGE SELLING PRICE, BY KEY PLAYER, 2025 (USD)
  • 5.6.2 AVERAGE SELLING PRICE TREND, BY REGION, 2023-2025 (USD)
    • 5.6.2.1 Rheumatoid arthritis
    • 5.6.2.2 Anaphylaxis
    • 5.6.2.3 Diabetes
    • 5.6.2.4 Obesity
• 5.7 TRADE ANALYSIS
  • 5.7.1 IMPORT DATA FOR HS CODE 901890
  • 5.7.2 EXPORT DATA FOR HS CODE 901890
• 5.8 REIMBURSEMENT SCENARIO
  • 5.8.1 KEY CONFERENCES & EVENTS (2025-2026)
• 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.10 INVESTMENT & FUNDING SCENARIO
• 5.11 CASE STUDY ANALYSIS
• 5.12 IMPACT OF US TARIFFS-AUTOINJECTORS MARKET
  • 5.12.1 INTRODUCTION
  • 5.12.2 KEY TARIFF RATES
  • 5.12.3 PRICE IMPACT ANALYSIS
  • 5.12.4 IMPACT ON COUNTRIES/REGIONS
    • 5.12.4.1 North America
    • 5.12.4.2 Asia Pacific
    • 5.12.4.3 Europe
    • 5.12.4.4 Latin America
  • 5.12.5 IMPACT ON END-USE SEGMENTS
• 5.13 DEVICES FOR LARGE-VOLUME FORMULATIONS
• 5.14 DEVICES FOR HIGHLY VISCOUS FORMULATIONS
• 5.15 INSIGHTS ON FUTURE AREAS OF FOCUS IN AUTOINJECTORS MARKET

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

• 6.1 KEY EMERGING TECHNOLOGIES
  • 6.1.1 INJECTION MECHANISM TECHNOLOGY
  • 6.1.2 ELECTRONIC AND CONNECTIVITY SOLUTIONS
• 6.2 COMPLEMENTARY TECHNOLOGIES
  • 6.2.1 POWER ASSISTANCE MECHANISMS
  • 6.2.2 ADVANCED NEEDLE TECHNOLOGY
  • 6.2.3 DRUG CONTAINER AND CARTRIDGE TECHNOLOGIES
• 6.3 ADJACENT TECHNOLOGIES
  • 6.3.1 WEARABLE DRUG DELIVERY DEVICES
  • 6.3.2 IMPLANTABLE DRUG DELIVERY SYSTEMS
  • 6.3.3 NEEDLE-FREE INJECTION TECHNOLOGY
• 6.4 TECHNOLOGY/PRODUCT ROADMAP
  • 6.4.1 NEAR TERM (2025-2027)
  • 6.4.2 MID-TERM (2028-2030)
  • 6.4.3 LONG TERM (2030+)
• 6.5 PATENT ANALYSIS
  • 6.5.1 JURISDICTION AND TOP APPLICANT ANALYSIS
• 6.6 FUTURE APPLICATIONS
  • 6.6.1 AI-ENABLED PERSONALIZED DRUG DELIVERY
  • 6.6.2 COMBINATION THERAPY DELIVERY
  • 6.6.3 REUSABLE AUTOINJECTOR PLATFORMS
• 6.7 IMPACT OF AI/GEN AI ON AUTOINJECTORS MARKET
  • 6.7.1 INTRODUCTION
  • 6.7.2 TOP USE CASES AND MARKET POTENTIAL
  • 6.7.3 BEST PRACTICES FOLLOWED BY MANUFACTURERS/OEMS IN AUTOINJECTORS MARKET

7 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

• 7.1 DECISION-MAKING PROCESS
• 7.2 KEY STAKEHOLDERS INVOLVED IN BUYING PROCESS AND THEIR EVALUATION CRITERIA
  • 7.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 7.2.2 BUYING CRITERIA
• 7.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
• 7.4 UNMET NEEDS OF VARIOUS END-USE INDUSTRIES
• 7.5 MARKET PROFITABILITY

8 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES

• 8.1 REGIONAL REGULATIONS AND COMPLIANCE
  • 8.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 8.1.2 REGULATORY FRAMEWORK
    • 8.1.2.1 North America
    • 8.1.2.2 Europe
    • 8.1.2.3 Asia Pacific
    • 8.1.2.4 Latin America
    • 8.1.2.5 Middle East & Africa
  • 8.1.3 CERTIFICATIONS, LABELING, ECO-STANDARDS
  • 8.1.4 INDUSTRY STANDARDS
• 8.2 SUSTAINABILITY INITIATIVES
  • 8.2.1 REUSABLE AUTOINJECTOR PLATFORMS
  • 8.2.2 USE OF BIO-BASED POLYMERS
  • 8.2.3 CIRCULAR DEVICE DESIGN AND RECYCLABILITY

9 AUTOINJECTORS MARKET, BY TYPE

• 9.1 INTRODUCTION
• 9.2 FINISHED FORMULATION AUTOINJECTORS
  • 9.2.1 READY-TO-USE DESIGN AND PATIENT CONVENIENCE DRIVE MARKET LEADERSHIP
• 9.3 AUTOINJECTOR DEVICES
  • 9.3.1 FLEXIBILITY AND PLATFORM-BASED INTEGRATION SUPPORT MARKET ADOPTION

10 AUTOINJECTORS MARKET, BY USAGE

• 10.1 INTRODUCTION
• 10.2 DISPOSABLE AUTOINJECTORS
  • 10.2.1 EASE OF USE AND REDUCED RISK OF NEEDLESTICK INJURIES TO PROPEL MARKET GROWTH
• 10.3 REUSABLE AUTOINJECTORS
  • 10.3.1 COST-EFFECTIVENESS, ADAPTABILITY, AND SUSTAINABILITY TO DRIVE MARKET EXPANSION

11 AUTOINJECTORS MARKET, BY ACTUATION MECHANISM

• 11.1 INTRODUCTION
• 11.2 MECHANICAL (SPRING-BASED) AUTOINJECTORS
  • 11.2.1 USER-FRIENDLY DESIGN AND INCREASED PATIENT CONTROL TO AUGMENT MARKET GROWTH
• 11.3 ELECTRONIC AUTOINJECTORS
  • 11.3.1 EASE OF ACCURATE DOCUMENTATION AND COMPREHENSIVE PATIENT RECORDS TO SUPPORT MARKET GROWTH

12 AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION

• 12.1 INTRODUCTION
• 12.2 SUBCUTANEOUS ADMINISTRATION
  • 12.2.1 EASE OF USE, RAPID ABSORPTION, AND SUITABILITY FOR SELF-ADMINISTRATION TO AID MARKET GROWTH
• 12.3 INTRAMUSCULAR ADMINISTRATION
  • 12.3.1 NEED FOR PRECISE DOSE DELIVERY IN EMERGENCY CLINICAL SETTINGS TO DRIVE MARKET

13 AUTOINJECTORS MARKET, BY THERAPY AREA

• 13.1 INTRODUCTION
• 13.2 RHEUMATOID ARTHRITIS
  • 13.2.1 HIGH DISEASE PREVALENCE AND NEED FOR FREQUENT DOSING TO DRIVE MARKET
• 13.3 DIABETES
  • 13.3.1 LARGE DIABETIC POPULATION AND EASE OF ADMINISTRATION TO STIMULATE DEMAND
• 13.4 ANAPHYLAXIS
  • 13.4.1 REQUIREMENT FOR PROMPT INITIAL TREATMENT FOR PATIENTS WITH FOOD ALLERGIES TO FUEL MARKET GROWTH
• 13.5 MULTIPLE SCLEROSIS
  • 13.5.1 AVAILABILITY OF COST-EFFECTIVE GENERIC ORAL MULTIPLE SCLEROSIS DRUGS TO LIMIT MARKET GROWTH
• 13.6 OBESITY
  • 13.6.1 INCREASING FOCUS ON WEIGHT MANAGEMENT TO BOOST MARKET GROWTH
• 13.7 OTHER THERAPY AREAS

14 AUTOINJECTORS MARKET, BY DRUG TYPE

• 14.1 INTRODUCTION
• 14.2 BIOLOGICS
  • 14.2.1 INCREASING USE IN INJECTABLE THERAPIES AND SELF-ADMINISTRATION TO DRIVE MARKET
• 14.3 BIOSIMILARS
  • 14.3.1 COST-EFFECTIVE ALTERNATIVES ACCELERATING MARKET EXPANSION
• 14.4 SMALL MOLECULES
  • 14.4.1 CRITICAL ROLE IN SELECTIVE INJECTABLES AND EMERGENCY USE CASES

15 AUTOINJECTORS MARKET, BY VOLUME

• 15.1 INTRODUCTION
• 15.2 UP TO 3ML
  • 15.2.1 RISING PREVALENCE OF AUTOIMMUNE DISORDERS AND LONG-TERM CHRONIC DISEASES TO PROPEL MARKET GROWTH
• 15.3 ABOVE 3ML
  • 15.3.1 INCREASING FOCUS ON COMPLEX TREATMENTS WITH HIGH-VISCOSITY DRUGS TO DRIVE THE MARKET

16 AUTOINJECTORS MARKET, BY END USER

• 16.1 AUTOINJECTOR DEVICE END USERS
  • 16.1.1 PHARMACEUTICAL & BIOTECH COMPANIES
    • 16.1.1.1 Expanding pipelines, advancements, and rising patient adherence to propel market
  • 16.1.2 CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS
    • 16.1.2.1 Growing trend of outsourcing and demand for specialized drug-device manufacturing capabilities support growth
• 16.2 FINISHED FORMULATION AUTOINJECTOR END USERS
  • 16.2.1 HOME CARE SETTINGS
    • 16.2.1.1 Cost-effectiveness and increased availability of home care support services to propel market growth
  • 16.2.2 HOSPITALS & CLINICS
    • 16.2.2.1 Technological advancements and availability of real-time patient data to support market growth
  • 16.2.3 AMBULATORY CARE CENTERS
    • 16.2.3.1 Growing demand for outpatient services to fuel market growth
  • 16.2.4 OTHER END USERS

17 AUTOINJECTORS MARKET, BY REGION

• 17.1 INTRODUCTION
• 17.2 NORTH AMERICA
  • 17.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 17.2.2 US
    • 17.2.2.1 US holds largest share in North American
  • 17.2.3 CANADA
    • 17.2.3.1 Aging population and increasing prevalence of allergies to propel market growth
• 17.3 EUROPE
  • 17.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 17.3.2 GERMANY
    • 17.3.2.1 Growing investments and increasing government spending on healthcare to drive market
  • 17.3.3 UK
    • 17.3.3.1 Increase in prevalence of lifestyle diseases and allergies supports demand growth
  • 17.3.4 FRANCE
    • 17.3.4.1 Favorable reimbursement policies and increased investment to drive market growth
  • 17.3.5 ITALY
    • 17.3.5.1 Rising elderly population pool to drive the market
  • 17.3.6 SPAIN
    • 17.3.6.1 Favorable reimbursement scenario and prevalence of chronic disease
  • 17.3.7 NETHERLANDS
    • 17.3.7.1 Strong healthcare system and aging population drive market growth
  • 17.3.8 REST OF EUROPE
• 17.4 ASIA PACIFIC
  • 17.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 17.4.2 JAPAN
    • 17.4.2.1 High healthcare expenditure, favorable reimbursement, and insurance coverage to support market growth
  • 17.4.3 CHINA
    • 17.4.3.1 Increase in prevalence of lifestyle diseases and allergies drives market growth
  • 17.4.4 INDIA
    • 17.4.4.1 Increasing burden of diabetes and cardiovascular diseases to spur market growth
  • 17.4.5 AUSTRALIA
    • 17.4.5.1 Growing older population and rising prevalence of target diseases to propel market
  • 17.4.6 SOUTH KOREA
    • 17.4.6.1 Rising obesity and chronic disease burden propel market growth
  • 17.4.7 THAILAND
    • 17.4.7.1 Rising geriatric population and chronic disease burden driving autoinjectors market growth
  • 17.4.8 VIETNAM
    • 17.4.8.1 Aging population and healthcare expansion aiding autoinjectors market growth in Vietnam
  • 17.4.9 REST OF ASIA PACIFIC
• 17.5 LATIN AMERICA
  • 17.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 17.5.2 BRAZIL
    • 17.5.2.1 Rising obesity to stimulate market growth
  • 17.5.3 MEXICO
    • 17.5.3.1 Rising disease burden to support market growth
  • 17.5.4 REST OF LATIN AMERICA
• 17.6 MIDDLE EAST & AFRICA
  • 17.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 17.6.2 GCC COUNTRIES
    • 17.6.2.1 Kingdom of Saudi Arabia (KSA)
      • 17.6.2.1.1 Strong public investments and rising trend of home care to propel market
    • 17.6.2.2 United Arab Emirates
      • 17.6.2.2.1 Favorable government strategies for health and infrastructure driving market growth
    • 17.6.2.3 Other GCC Countries
  • 17.6.3 REST OF MIDDLE EAST & AFRICA

18 COMPETITIVE LANDSCAPE

• 18.1 INTRODUCTION
• 18.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2022-2026
  • 18.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN AUTOINJECTORS MARKET
• 18.3 REVENUE ANALYSIS, 2023-2025
  • 18.3.1 REVENUE ANALYSIS: AUTOINJECTOR DEVICES MARKET
  • 18.3.2 REVENUE ANALYSIS: FINISHED FORMULATION AUTOINJECTORS MARKET
• 18.4 MARKET SHARE ANALYSIS, 2025
  • 18.4.1 MARKET SHARE ANALYSIS: AUTOINJECTOR DEVICES MARKET
  • 18.4.2 MARKET SHARE ANALYSIS: FINISHED FORMULATION AUTOINJECTORS MARKET
• 18.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
  • 18.5.1 AUTOINJECTOR DEVICES MARKET
    • 18.5.1.1 Stars
    • 18.5.1.2 Emerging leaders
    • 18.5.1.3 Pervasive players
    • 18.5.1.4 Participants
    • 18.5.1.5 Company footprint: key players, 2025
      • 18.5.1.5.1 Company footprint
      • 18.5.1.5.2 Region footprint
      • 18.5.1.5.3 Usage footprint
      • 18.5.1.5.4 Volume footprint
      • 18.5.1.5.5 Route of administration footprint
  • 18.5.2 FINISHED FORMULATION AUTOINJECTORS MARKET
    • 18.5.2.1 Stars
    • 18.5.2.2 Emerging leaders
    • 18.5.2.3 Pervasive players
    • 18.5.2.4 Participants
    • 18.5.2.5 Company footprint: key players, 2025
      • 18.5.2.5.1 Company footprint
      • 18.5.2.5.2 Region footprint
      • 18.5.2.5.3 Usage footprint
      • 18.5.2.5.4 Volume footprint
      • 18.5.2.5.5 Route of administration footprint
• 18.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
  • 18.6.1 AUTOINJECTOR DEVICES MARKET
    • 18.6.1.1 Progressive companies
    • 18.6.1.2 Responsive companies
    • 18.6.1.3 Dynamic companies
    • 18.6.1.4 Starting blocks
    • 18.6.1.5 Competitive benchmarking: Startups/SMEs, 2025
    • 18.6.1.6 Competitive benchmarking of key startup/SME players
  • 18.6.2 FINISHED FORMULATION AUTOINJECTORS MARKET
    • 18.6.2.1 Progressive companies
    • 18.6.2.2 Responsive companies
    • 18.6.2.3 Dynamic companies
    • 18.6.2.4 Starting blocks
    • 18.6.2.5 Competitive benchmarking: startups/SMEs, 2025
    • 18.6.2.6 Competitive benchmarking of key startup/SME players
• 18.7 COMPANY VALUATION AND FINANCIAL METRICS
  • 18.7.1 FINANCIAL METRICS
  • 18.7.2 COMPANY VALUATION
• 18.8 BRAND COMPARISON
• 18.9 COMPETITIVE SCENARIO
  • 18.9.1 PRODUCT LAUNCHES & APPROVALS
  • 18.9.2 DEALS
  • 18.9.3 EXPANSIONS
  • 18.9.4 PRODUCT LAUNCHES & APPROVALS
  • 18.9.5 DEALS
  • 18.9.6 EXPANSIONS

19 COMPANY PROFILES

• 19.1 KEY PLAYERS: AUTOINJECTOR DEVICES MARKET
  • 19.1.1 SHL MEDICAL AG
    • 19.1.1.1 Business overview
    • 19.1.1.2 Products offered
    • 19.1.1.3 Recent developments
      • 19.1.1.3.1 Product launches
      • 19.1.1.3.2 Deals
      • 19.1.1.3.3 Expansions
    • 19.1.1.4 MnM view
      • 19.1.1.4.1 Key strengths
      • 19.1.1.4.2 Strategic choices
      • 19.1.1.4.3 Weaknesses and competitive threats
  • 19.1.2 YPSOMED AG
    • 19.1.2.1 Business overview
    • 19.1.2.2 Products offered
    • 19.1.2.3 Recent developments
      • 19.1.2.3.1 Product launches
      • 19.1.2.3.2 Deals
      • 19.1.2.3.3 Expansions
    • 19.1.2.4 MnM view
      • 19.1.2.4.1 Key strengths
      • 19.1.2.4.2 Strategic choices
      • 19.1.2.4.3 Weaknesses and competitive threats
  • 19.1.3 WEST PHARMACEUTICAL SERVICES, INC.
    • 19.1.3.1 Business overview
    • 19.1.3.2 Products offered
    • 19.1.3.3 Recent developments
      • 19.1.3.3.1 Expansions
    • 19.1.3.4 MnM view
      • 19.1.3.4.1 Key strengths
      • 19.1.3.4.2 Strategic choices
      • 19.1.3.4.3 Weaknesses and competitive threats
  • 19.1.4 BECTON, DICKINSON AND COMPANY (BD)
    • 19.1.4.1 Business overview
    • 19.1.4.2 Products offered
    • 19.1.4.3 Recent developments
      • 19.1.4.3.1 Deals
    • 19.1.4.4 MnM view
      • 19.1.4.4.1 Key strengths
      • 19.1.4.4.2 Strategic choices
      • 19.1.4.4.3 Weaknesses and competitive threats
  • 19.1.5 PHILLIPS-MEDISIZE
    • 19.1.5.1 Business overview
    • 19.1.5.2 Products offered
    • 19.1.5.3 Recent developments
      • 19.1.5.3.1 Expansions
  • 19.1.6 HALOZYME, INC.
    • 19.1.6.1 Business overview
    • 19.1.6.2 Products offered
  • 19.1.7 OWEN MUMFORD
    • 19.1.7.1 Business overview
    • 19.1.7.2 Products offered
    • 19.1.7.3 Recent developments
      • 19.1.7.3.1 Product launches
      • 19.1.7.3.2 Deals
• 19.2 KEY PLAYERS: FINISHED FORMULATION AUTOINJECTORS MARKET
  • 19.2.1 ELI LILLY AND COMPANY
    • 19.2.1.1 Business overview
    • 19.2.1.2 Products offered
    • 19.2.1.3 Recent developments
      • 19.2.1.3.1 Product approvals
      • 19.2.1.3.2 Deals
      • 19.2.1.3.3 Expansions
    • 19.2.1.4 MnM view
      • 19.2.1.4.1 Key strengths
      • 19.2.1.4.2 Strategic choices
      • 19.2.1.4.3 Weaknesses and competitive threats
  • 19.2.2 ABBVIE INC.
    • 19.2.2.1 Business overview
    • 19.2.2.2 Products offered
    • 19.2.2.3 Recent developments
      • 19.2.2.3.1 Product approvals
      • 19.2.2.3.2 Deals
    • 19.2.2.4 MnM view
      • 19.2.2.4.1 Key strengths
      • 19.2.2.4.2 Strategic choices
      • 19.2.2.4.3 Weaknesses and competitive threats
  • 19.2.3 SANOFI
    • 19.2.3.1 Business overview
    • 19.2.3.2 Products offered
    • 19.2.3.3 Recent developments
      • 19.2.3.3.1 Product approvals
    • 19.2.3.4 MnM view
      • 19.2.3.4.1 Key strengths
      • 19.2.3.4.2 Strategic choices
      • 19.2.3.4.3 Weaknesses and competitive threats
  • 19.2.4 NOVO NORDISK A/S
    • 19.2.4.1 Business overview
    • 19.2.4.2 Products offered
    • 19.2.4.3 Recent developments
      • 19.2.4.3.1 Product approvals
      • 19.2.4.3.2 Deals
      • 19.2.4.3.3 Expansions
      • 19.2.4.3.4 Other developments
  • 19.2.5 AMGEN INC.
    • 19.2.5.1 Business overview
    • 19.2.5.2 Products offered
    • 19.2.5.3 Recent developments
      • 19.2.5.3.1 Product launches
      • 19.2.5.3.2 Expansions
      • 19.2.5.3.3 Other developments
  • 19.2.6 JOHNSON & JOHNSON
    • 19.2.6.1 Business overview
    • 19.2.6.2 Products offered
    • 19.2.6.3 Recent developments
      • 19.2.6.3.1 Product approvals
      • 19.2.6.3.2 Other developments
  • 19.2.7 GSK PLC
    • 19.2.7.1 Business overview
    • 19.2.7.2 Products offered
    • 19.2.7.3 Recent developments
      • 19.2.7.3.1 Product approvals
  • 19.2.8 ASTRAZENECA
    • 19.2.8.1 Business overview
    • 19.2.8.2 Products offered
    • 19.2.8.3 Recent developments
      • 19.2.8.3.1 Product approvals
      • 19.2.8.3.2 Deals
      • 19.2.8.3.3 Expansions
      • 19.2.8.3.4 Other developments
• 19.3 OTHER PLAYERS
  • 19.3.1 GERRESHEIMER AG
  • 19.3.2 HASELMEIER GMBH
  • 19.3.3 SMC LTD
  • 19.3.4 KALEO, INC.
  • 19.3.5 SOLTEAM INCORPORATION CO., LTD.
  • 19.3.6 ELCAM DRUG DELIVERY DEVICES
  • 19.3.7 CROSSJECT
  • 19.3.8 JABIL, INC.
  • 19.3.9 CONGRUENCE MEDICAL SOLUTIONS LLC
  • 19.3.10 MIDAS PHARMA GMBH
  • 19.3.11 XERIS PHARMACEUTICALS, INC.
  • 19.3.12 WINDGAP MEDICAL, INC
  • 19.3.13 ALTAVIZ

20 RESEARCH METHODOLOGY

• 20.1 RESEARCH DATA
• 20.2 RESEARCH METHODOLOGY DESIGN
  • 20.2.1 SECONDARY DATA
    • 20.2.1.1 Key data from secondary sources
  • 20.2.2 PRIMARY DATA
    • 20.2.2.1 Key industry insights
• 20.3 MARKET SIZE ESTIMATION: AUTOINJECTOR DEVICES
• 20.4 MARKET SIZE ESTIMATION: FINISHED FORMULATIONS
  • 20.4.1 SEGMENTAL MARKET ESTIMATION (TOP-DOWN APPROACH)
• 20.5 MARKET GROWTH RATE PROJECTIONS
• 20.6 DATA TRIANGULATION
• 20.7 MARKET SHARE ANALYSIS
• 20.8 RESEARCH ASSUMPTIONS
  • 20.8.1 GROWTH RATE ASSUMPTIONS
• 20.9 RISK ASSESSMENT
• 20.10 LIMITATIONS
  • 20.10.1 METHODOLOGY-RELATED LIMITATIONS
  • 20.10.2 SCOPE-RELATED LIMITATIONS
• 20.11 RISK ANALYSIS

21 APPENDIX

• 21.1 DISCUSSION GUIDE
• 21.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 21.3 CUSTOMIZATION OPTIONS
  • 21.3.1 COMPANY INFORMATION
  • 21.3.2 GEOGRAPHIC ANALYSIS
  • 21.3.3 REGIONAL/COUNTRY-LEVEL MARKET SHARE ANALYSIS
  • 21.3.4 COUNTRY-LEVEL VOLUME ANALYSIS
  • 21.3.5 ANY CONSULTS/CUSTOM REQUIREMENTS AS PER CLIENT REQUEST
• 21.4 RELATED REPORTS
• 21.5 AUTHOR DETAILS